ID   GR-Mel-9
AC   CVCL_C499
DR   Cosmic; 2163846
DR   ESTDAB; ESTDAB-159
DR   Wikidata; Q54871660
RX   PubMed=19340423;
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys135Ser (c.404G>C); Zygosity=Unspecified (PubMed=23851445).
ST   Source(s): ESTDAB=ESTDAB-159
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   FGA: 21,24
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 12
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//